Buformin (hydrochloride)

Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) [1].

Product Specifications

CAS Number

[1190-53-0]

Product Name Alternative

1-Butylbiguanide (hydrochloride)

UNSPSC

12352211

Hazard Statement

H302, H315, H318, H335

Target

AMPK

Type

Reference compound

Related Pathways

Epigenetics; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/buformin-hydrochloride.html

Purity

99.91

Solubility

DMSO : 125 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

NC(NC(NCCCC)=N)=N.[H]Cl

Molecular Formula

C6H16ClN5

Molecular Weight

193.68

Precautions

H302, H315, H318, H335

References & Citations

[1]Amanda B Parris, et al. Buformin hydrochloride Inhibits the Stemness of erbB-2-overexpressing Breast Cancer Cells and Premalignant Mammary Tissues of MMTV-erbB-2 Transgenic Mice. J Exp Clin Cancer Res|[2]Jing Li, et al. Buformin hydrochloride Suppresses Proliferation and Invasion via AMPK/S6 Pathway in Cervical Cancer and Synergizes With Paclitaxel. Cancer Biol Ther. 2018 Jun 3;19 (6) :507-517.